Identification of Biomarkers in an Oral Malignant Melanoma Case with Potential for Therapeutic Intervention

R Pai, S Pai, R Lalitha, S Kumaraswamy, N Lalitha, R Johnston, M Bhargava

Citation

Abstract
A 32-year old female patient presented with the tumor of the oral cavity at the Kidwai Memorial Institute of Oncology, Bangalore, India. Clinical examination and histopathological analyses confirmed the neoplasm as malignant melanoma. This rare melanoma of the buccal mucosa expressed carcinoembryonic antigen (CEA) as well as contained cells that expressed elevated levels of the c-myc oncogene product as identified by immunohistochemistry of the tumor biopsy. Presence of these tumor makers in the rare case of malignant melanoma with poor prognosis should allow exploration of novel targeted therapy against CEA and c-Myc.

INTRODUCTION
In South Indian population, prevalence of long term chewing habits of betel leaves, areca nut and tobacco culminates in the genesis of the neoplasms of the oral cavity in a large fraction of the habitual users. Majority of head and neck cancers presented at our institution are oral squamous cell carcinoma (OSCC). However, occasionally cases of malignant melanomas are encountered in the oral cavity. Oral malignant melanoma is a rare entity occurring at a frequency of less than 2% of the all the head and neck cancers. When melanocytes or their precursor cells become neoplastic, they lead to malignancies which usually metastasize to adjacent tissues. Hence, malignant melanomas are difficult to treat with poor prognosis. They are also known to be aggressive tumors and spread to tissues adjacent to the primary tumor and are resistant to radiation and chemotherapy. Treatments of melanomas which are refractory to conventional modalities of therapy pose a problem to clinicians. Hence, novel modalities of treatment such as immunotherapy and anti-sense therapy need to be explored to combat the disease. One of the targets to be considered for successful treatment of such tumors could be the carcinoembryonic antigen (CEA) against which immunotherapies are being developed. Therefore, identification of tumor markers such as CEA and c-Myc in this form of malignancy could be very beneficial in treating this malady.

CASE REPORT
Characteristics of the Tumor: The tumor was localized on the palate (Figure 1).

devolved, which is an approach that is being pursued by several researchers. Therefore, identification of tumor markers such as CEA and c-Myc in this form of malignancy could be very beneficial in treating this malady.
Examination of the Level 2, 3 nodes showed metastases whereas level 4,5 nodes were free of the tumor. Histopathological analyses confirmed the tumor to be malignant melanoma. Microscopic sections revealed epitheloid pigmented cells arranged in nests, invading the underlying connective tissue. Focal areas showed atypical, pigmented spindle shaped cells with fascicular arrangement. Cells showed clear cytoplasm with large nuclei and prominent nucleoli. Few cells showed pleomorphism and nuclear hyperchromatism. Sparse inflammatory infiltrate was seen in connective tissue.

Immunohistochemical characterization of the tumor tissue sections were carried out for identification of CEA. The tumor cells were positive for anti-CEA reactivity suggesting the expression of the biomarker CEA by the melanoma cells (Fig. 2A). When the procedure was employed using anti-Myc antibodies, positive staining was observed in a few cells in the tumor (Figure 2B). Immunostaining of tumor tissue sections performed by omission of the antibodies in the assay showed no staining indicating the specificity of the reaction (Fig. 2C).

DISCUSSION

Initiation of oral neoplasia in the South Indian population is contributed to a large extent due to the betel chewing habits. The physical insult of retaining the quid in the oral cavity for extended periods of time coupled to the interaction of the chemical components results in the neoplastic progression. Even though majority of the tumors are OSCC, rare cases of malignant melanomas are presented. These are of interest due to their location, aggressive nature as well as difficulty in clinical management by conventional modalities of treatment resulting in poor prognosis. Hence, novel treatment protocols are warranted to successfully manage oral malignant melanomas. To this end, we investigated the expression of CEA and c-Myc in a rare case of oral
malignant melanoma.

CEA is expressed in a large number of tumors including the malignant melanomas and its presence is known to contribute towards an aberrant phenotype in some melanomas. M 21 melanoma cells derived from xenografts have also been shown to express CEA. Duray et al. detected CEA in primary as well as metastatic melanomas using monoclonal antibodies. Elevated expression of CEA has also been documented in metastatic melanoma of cutaneous origin. Other head and neck cancers such as submandibular gland carcinomas are also known to express CEA. CEA is also considered as an important circulating biomarker in oral cancers.

Another important biomarker in melanomas is the oncoprotein c-Myc. Increase in the expression of the c-Myc oncogene is known to be a hallmark of enhanced proliferation potential. Observations from cutaneous malignant melanoma exhibited an increase in mitotic rate with concomitant increase in c-Myc expression. Moderate increases in the amounts of the oncogene c-Myc in metastatic melanomas has also been reported.

The rarity of oral melanomas and poor prognosis necessitates characterization of this class of neoplasms for efficacious management. To the best of our knowledge, this is the first report of a malignant melanoma of the oral cavity which expresses CEA identified by immunohistochemistry. We have recently reported the expression of CEA in OSCC and it is interesting to note that the rare malignant melanoma we studied also share this property.

We could also identify a few cells that express c-Myc in this malignant melanoma from the palate region. These cells could be the cells which have increased mitotic rate as described by other investigators in cutaneous melanoma cases. The c-Myc protein is suggested to be a significant contributor for malignant progression of melanomas and the over-expression of this oncogene leads to poor prognosis for this class of tumors. In addition, c-Myc is considered an independent prognostic marker in the case of primary melanomas and in metastatic melanomas. This oncoprotein is known to be associated with the development of neoplastic transformation in oral cancers as well.

Melanomas of the oral cavity are not only rare types of tumors but are also aggressive and have a great potential to metastasize especially exhibiting hematogenous invasion and have poor prognosis when compared to the cutaneous melanomas. Antibody mediated therapy especially against CEA may be important in designing efficient treatment protocols. Several immunotherapeutic approaches using CEA are currently underway and successful clinical trials of these entities should hold promise for employing these strategies against CEA-expressing oral malignant melanomas. While other therapeutic options are also being explored, the down regulation of c-Myc using liposomal c-Myc antisense oligonucleotide which is known to inhibit the growth and metastases of human melanomas as well as combination of c-Myc therapy and conventional chemotherapeutic agents such as doxorubicin could also lead to efficient treatment modalities for oral malignant lesions.

ACKNOWLEDGEMENTS

The study was supported by the Indian Council of Medical Research, New Delhi, India.

References

11. Muramatsu T, Hashimoto S, Lee MW, Chung CK, Matsuzaki K, Inoue N, Noma H, Shimono M. Oncocytic...
Author Information

Rekha B. Pai, PhD
Georgia Institute of Technology

S. Balakrishna Pai, PhD
Georgia Institute of Technology

R. M. Lalitha, MDS
Department of Oral and Maxillofacial Surgery, M.S. Ramaiah Dental College and Hospital

S.V. Kumaraswamy, MDS
V.S. Dental College and Hospital

N. Lalitha, MD
Kidwai Memorial Institute of Oncology

Randal N. Johnston, PhD
Department of Biochemistry and Molecular Biology, The University of Calgary

M. Krishna Bhargava, MD
Kidwai Memorial Institute of Oncology